Premium
Erectile dysfunction, sildenafil and cardiovascular risk
Author(s) -
Chew K Kim,
Stuckey Bronwyn GA,
Thompson Peter L
Publication year - 2000
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.2000.tb123945.x
Subject(s) - sildenafil , erectile dysfunction , medicine , ischaemic heart disease , disease , cardiology
Cardiovascular risk factors are commonly associated with erectile dysfunction and should be identified and treated. Patients with cardiovascular diseases should be assessed and counselled regarding their fitness for sexual activity. The danger of concurrent use of sildenafil and nitrates under any circumstances, regardless of age and sex, must be highlighted at all levels of the community. Sildenafil is absolutely contraindicated in patients receiving treatment with long‐acting nitrates for ischaemic heart disease. Patients who need sublingual short‐acting nitrates infrequently should not be precluded from taking sildenafil, provided they are aware that sildenafil is not to be taken within 24 h of taking the nitrate.